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Abstract: Background and objectives: Preeclampsia (PE) is a risk factor for kidney diseases; egg-donation
(ED) increasingly used for overcoming fertility reduction, is a risk factor for PE. CKD is also a risk
factor for PE. However, kidney function is not routinely assessed in ED pregnancies. Objective of
the study is seeking to assess the importance of kidney function and maternal comorbidity in ED
pregnancies. Design, setting, participants and measurements. Design: retrospective observational
study from clinical charts. Setting: Sant’Anna Hospital, Turin, Italy (over 7000 deliveries per year).
Selection: cases: 296 singleton pregnancies from ED (gestation > 24 weeks), who delivered January
2008–February 2019. Controls were selected from the TOrino Cagliari Observational Study (1407 low-risk
singleton pregnancies 2009–2016). Measurements: Standard descriptive analysis. Logistic multiple
regression analysis tested: PE; pregnancy-induced hypertension; preterm delivery; small for gestational
age; explicatory variables: age; BMI; parity; comorbidity (kidney diseases; immunologic diseases; thyroid
diseases; other). Delivery over time was analyzed according to Kaplan Meier; ROC (Relative Operating
Characteristic) curves were tested for PE and pre-term delivery, employing serum creatinine and e-GFR
as continuous variables. The analysis was performed with SPSS v.14.0 and MedCalc v.18. Results: In
keeping with ED indications, maternal age was high (44 years). Comorbidity was common: at least
one potential comorbid factor was found in about 40% of the cases (kidney disease: 3.7%, immunologic
6.4%, thyroid disease 18.9%, other-including hypertension, previous neoplasia and all other relevant
diseases—10.8%). No difference in age, parity and BMI is observed in ED women with and without
comorbidity. Patients with baseline renal disease or “other” comorbidity had a higher risk of developing
PE or preterm delivery after ED. PE was recorded in 23% vs. 9%, OR: 2.513 (CI 1.066–5.923; p = 0.039);
preterm delivery: 30.2% vs. 14%, OR 2.565 (CI: 1.198–5.488; p = 0.044). Limiting the analysis to 124
cases (41.9%) with available serum creatinine measurement, higher serum creatinine (dichotomised
at the median: 0.67 mg/dL) was correlated with risk of PE (multivariate OR 17.277 (CI: 5.125–58.238))
and preterm delivery (multivariate OR 2.545 (CI: 1.100–5.892). Conclusions: Within the limits of a
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retrospective analysis, this study suggests that the risk of PE after ED is modulated by comorbidity.
While the cause effect relationship is difficult to ascertain, the relationship between serum creatinine and
outcomes suggests that more attention is needed to baseline kidney function and comorbidity.
Keywords: pregnancy; egg donation; preterm delivery; preeclampsia; kidney function
1. Introduction
As egg donation has increasingly come to be used as an assisted fertilization technique, its main
role has progressively shifted from making pregnancy possible in patients with primary or early ovarian
failure, or with severe genetic diseases, to extending the age of pregnancy beyond the physiological
limit of fertility [1–3].
Notwithstanding the indications, egg donation is associated with a higher risk of virtually all
adverse pregnancy outcomes, including caesarean section, preterm delivery, small for gestational age
babies and the hypertensive disorders of pregnancy [4–9]. A number of elements seem to contribute to
increased risk: among them, the most commonly studied ones are advanced maternal age, multiple
pregnancies, and the presence of specific diseases that cause infertility [10–12].
The risks of adverse pregnancy-related outcomes are at least in part linked to the procedure
used. As a general rule, the more complex the procedure, the higher the risk; in vitro fertilisation is
the most complex procedure, and the one with the highest risk [13,14]. Furthermore, immunologic
factors probably play an important role, and the studies comparing pregnancy after homologous
fertilisation and egg donation have reported an increased incidence of adverse events in the latter, in
which the oocytes are 100% genetically different from the mother’s. Some studies suggest that HLA
compatibility may be an important issue, leading some authors to consider egg donation as a form of
“transplantation” without immunosuppression [15–19].
Even if the increase in comorbid conditions that goes along with maternal age is often mentioned
as a possible cause for increased adverse pregnancy outcomes in egg-donor pregnancies, in which
maternal age is usually higher, to date no study has focused on different comorbidity and, in this context,
the “missing piece” is an analysis of kidney function, which is closely associated with pregnancy
outcomes [20–27].
It was in this context that we undertook the present retrospective analysis. Our aim is to assess
the prevalence and the role of the main comorbid conditions, with particular attention to the presence
of autoimmune and kidney diseases, and to try to understand how they affect the main pregnancy
outcomes in singleton pregnancies from heterologous egg donation. Furthermore, the relationship
between kidney function data was explored in patients who had at least one available creatinine test
during pregnancy or at delivery.
2. Methods
2.1. Setting of Study
The study was performed at Ospedale Sant’Anna, a tertiary-care hospital, that is part of the Città della
Salute e della Scienza in Torino, Italy; the low-risk controls were obtained from the archives of the Torino
Cagliari Observational Study (TOCOS), dedicated to women with CKD, described elsewhere [21,24].
With an average of over 7000 deliveries per year, Sant’Anna Hospital is one of the largest European
tertiary care obstetric facilities.
Egg donation has only been available in Italy since 2014–2015 and even now, many restrictions
apply to its use, in particular in high maternal age. Therefore, until 2015 patients who decided to have
egg-donation pregnancies travelled outside the country, mainly to Spain, where these procedures are
legal. As a consequence, pre-conception data are usually not available.
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2.2. Selection of the Cases
2.2.1. Egg-Donation
The selection of the cases of pregnancy in women undergoing egg-donation included all patients
who delivered at the Sant’Anna Hospital between January 2008 and February 2019.
Pregnancies from egg-donation were identified in two main sources: the first was the hospital’s
discharge database in which medical history, birth data and discharge letters are recorded. The search
was carried out using the Italian keywords related to “egg-donation” in various combinations
(e.g., “ovodonazione, ovodonazioni, ED eterologa, OD, fecondazione eterologa”). Secondly, we
searched the computerised records of pregnant women referred to the Prenatal Screening Center at the
Sant’ Anna Hospital, where information on type of conception is mandatorily recorded (egg-donation,
other types of assisted fertilisation techniques, spontaneous pregnancy).
2.2.2. Low-Risk PREGNANCIES
Low-risk pregnancies were selected from the TOCOS archives (TOrino Cagliari Observational
Study [21,24]). In this study, low-risk pregnancy is defined as a spontaneous singleton pregnancy
occurring in a woman without pre-existing, systemic and localized diseases. The database presently
gathers 1407 Low-risk singleton pregnancies observed in the two settings in the period 2009–2016.
2.3. Selection Criteria
From the available databases, we selected singleton pregnancies with a duration of more than
24 weeks, with complete data at delivery (gestational week, maternal age, birth centile). Abortions and
therapeutic interruptions of pregnancy were excluded from the study.
2.4. Data Recorded
The following data regarding egg donation pregnancies were recorded:
• age, ethnicity, parity, baseline BMI; hypertension (pre-existing and gestational); diabetes (previous
and gestational);
• diagnosis of PE; diagnosis of HELLP syndrome; gestational week of delivery, type of delivery;
baby’s weight at birth, centile;
• need for maternal intensive care unit, need for neonatal intensive care unit, perinatal death,
maternal death;
Whenever available, the following information was also included: previous PE, previous
miscarriages, any other maternal disease; previous assisted fertilization; family history of CKD,
cardiovascular disorders or preeclampsia.
Serum creatinine was recorded whenever available in the clinical charts or in the hospital
laboratory records before and during hospitalization. Jaffé Method was employed up to 2017, when it
was substituted by the enzymatic method.
2.5. Statistical Analysis
Descriptive analysis was conducted as appropriate. The Shapiro Test was used to verify the
normality distribution of the data. Median and min-max or range was used for non-parametric data,
mean, and standard deviation for normal distribution.
Statistical significance was assessed using ANOVA for parametric data and Kruskal-Wallis for
non-parametric data, in compliance with standard indications for continuous variables. Dichotomous
data are presented as risks, rates and proportions; in this case, the significance of the differences was
analysed using the Chi-Square Test.
The significance of differences between groups was assessed using the t-test for normally
distributed variables and the Wilcoxon Signed Rank Test for variables that were not normally distributed.
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Logistic multiple regression analysis was performed for the covariates that emerged as significant in
the descriptive analysis or were considered clinically relevant on the basis of the current understanding
of the literature. Different outcomes were tested: preterm delivery (<37, <34 and <32 completed
gestational weeks); small for gestational age baby (SGA, defined as < 5 and <10 centile, according the
Italian birth reference charts, InES charts); preeclampsia (PE); pregnancy-induced hypertension (PIH);
for this latter, only cases that were normotensive before pregnancy were considered. For the present
study, we selected the outcomes of preterm delivery (<37 weeks), SGA < 10 centile and PE.
The outcomes were tested in the whole population of egg-donation pregnancies and in the subset
of cases in which at least one serum creatinine assessment was available.
The following dichotomized covariates were tested: age (dichotomized at the median); BMI
(dichotomized at pre-gestational BMI of 30 kg/m2); parity (primiparous versus multiparous); presence
of comorbidity (the following categories were assessed: thyroid diseases; immunologic diseases;
kidney diseases; other relevant comorbidities, including diabetes, hypertension, history of neoplasia,
genetic diseases; since immunologic and thyroid diseases needed to be in full remission or complete
control, we tested both all comorbid conditions and kidney and other relevant diseases only).
Analysis of delivery over time was conducted according to Kapan Meier (outcome: timing of
delivery; stratification according to comorbidity, testing the two subsets with all comorbid conditions
and kidney diseases plus other relevant comorbidities); comparison between curves was made using
the Log-Rank Test.
ROC curves were tested for the outcomes’ pre-term delivery and preeclampsia, employing serum
creatinine and e-GFR as continuous variables.
The analysis was performed with SPSS software v.14.0 (IMB Corp., Chicago, IL, USA) and MedCalc
v.18 (MedCalc Software bvba, Ostend, Belgium).
2.6. Ethical Issues
This is an observational retrospective study, encompassing an analysis of the clinical charts of
women who delivered after egg donation in a single Italian center in the years 2017–2018; the aim
of the study was to detect predisposing factors. All patients evaluated in the present study signed,
at time of hospitalization, a standard consent form, authorizing anonymous data management and
publication. The study was notified to the hospital’s ethics committee.
3. Results
3.1. Characteristics of the Population
Table 1 summarizes the main characteristics of the study population. In keeping with what is
known about egg-donor pregnancies, this cohort has a higher age at delivery, and a higher incidence
of primiparity. About 40% of the cases display at least one comorbid condition, of which thyroid
disorders are the ones most frequently reported. Immunologic disorders were also relatively frequent.
Due to the fact that both needed to be in full remission-compensation as a requisite for egg donation,
we further considered them separately, including or excluding them in the comorbidity analysis.
As expected, pregnancy-related adverse outcomes have a significantly higher incidence in the
cohort of patients fertilized through egg donation, compared with low-risk pregnancies. The differences
remain highly significant when only “no- risk” patients are considered.
It is important to emphasize that the preeclampsia rate is of 11.1% after egg donation as compared
1.7% in low risk controls, and that they have 3.7% vs. 0.5% of early preterm babies (<32 weeks, OR 7.7)
while, quite surprisingly, SGA rate differs only when specific comorbidities are considered. Further,
it is of note that women who underwent egg donation have a significantly higher incidence of LGA
babies (12.5% vs. 7.6% in controls).
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Table 1. Baseline and main delivery data in pregnancies from egg donation and in controls.
Whole Population Egg Donation
Egg donation
(n = 296)
Controls
(n = 1407) p-Values
No Conorbidity
(n = 178)
Comorbidity
(n = 118) p-Values
Age (years), median
(min–max) 44 (31–56) 31 (15–49) <0.0001 44 (31–56) 43 (33–52) 0.3797
Parity, n. first (%) 259 (87.5%) 803 (57.1%) <0.0001 151 (84.8%) 108 (91.5%) 0.0887
BMI (kg·m−2), median
(min–max)
22.7
(15.6–35.5)
22.4
(15.0–39.7) 0.9102
22.7
(16.8–33.7)
23.6
(15.6–35.5) 0.9598
Hypertension during
pregnancy, n (%) * 74 (25.0%) - - 31 (17.4%) 43 (36.4%) 0.0002
Gestational
hypertension, n (%) 60 (20.3%) - - 31 (17.4%) 29 (24.6%) 0.1342
Preeclampsia, n (%) 33 (11.1%) 24 (1.7%) <0.0001 16 (9.0%) 17 (14.4%) 0.1477
Centiles at birth, median
(min–max) 55 (0–100) 45 (0–100) 0.0051 60 (1–100) 48 (0–100) 0.0071
Creatinine (mg·dL−1),
median (min–max)/n
0.67
(0.26–1.94) / 124 - -
0.67
(0.26–1.94) /61
0.68
(0.46–1.70) /63 0.3197
eGFR-EPI (mL·min−1),
median (min–max)
103
(31–151) - -
103
(33–151) / 61
103
(31–129) / 63 0.7929
GFR < 90 (mL·min−1), n
(%)
38 (30.6%) - - 18 (29.5%) /61 20 (31.7%) /63 0.7878
Caesarean section, n (%) 210 (70.9%) 265 (23.6%) <0.0001 128 (71.9%) 82 (69.5%) 0.6542
Size for GA
Small, n (%)
Adequate, n (%)
Large, n (%)
27 (9.1%)
232 (78.4%)
37 (12.5%)
142 (10.1%)
1154 (82.0%)
107 (7.6%)
0.0230 12 (6.7%)138 (77.5%)
28 (15.8%)
15 (12.7%)
94 (79.7%)
9 (7.6%)
0.0380
Pre-term
<37 weeks, n (%)
<34 weeks, n (%)
<32 weeks, n (%)
48 (16.2%)
18 (6.1%)
11 (3.7%)
88 (6.3%)
13 (0.9%)
7 (0.5%)
<0.0001
<0.0001
<0.0001
24 (13.5%)
10 (12.8%)
7 (3.9%)
24 (20.3%)
8 (6.8%)
4 (3.4%)
0.1178
0.6827
0.8093
eGFR EPI: glomerular filtration rate calculated with the CKD-EPI formula; BMI: body mass index; GA: gestational
age. HT Hypertension. * Hypertension in pregnancy: all cases regardless of previous hypertension. Gestational
hypertension is hypertension during pregnancy in previously normotensive patients. Significant results in bold.
No difference in age, parity and BMI is observed in women with and without comorbid conditions
who had been fertilized through egg donation. Conversely, a trend towards an increase in adverse
pregnancy-related events is observed in patients with comorbidity who had received egg donation
(all conditions together) and the difference reaches statistical significance for gestational hypertension,
centiles and incidence of small for gestational age babies, which is roughly double in “at risk” mothers.
3.2. Relationship between Comorbidity and Outcomes
The most commonly reported comorbid condition found was thyroid disease. Chronic kidney
disease was present in 11 patients (3.7%). The diagnoses were kidney malformations (3); glomerular
diseases (2); lupus nephropathy (3); kidney stones (2); diabetic nephropathy (1). One patient, previously
on dialysis for lupus nephropathy, was a kidney graft recipient at the time of egg donation. She was
the only one who was followed up in a nephrology-obstetric outpatient facility.
Other comorbid conditions included: chronic hypertension (10 cases without CKD); cardiopathy (4);
previous neoplasia treated by chemotherapy (5); fragile X or trisomy X syndromes (3); MTHFR
homozygous mutation (5); other causes (5).
The different “risk factors” do not appear to have the same weight. Thyroid diseases and other
autoimmune diseases, do not appear to affect the risk of developing preeclampsia and of having a small
for gestational age baby, or preterm delivery, as happens with kidney diseases and other comorbid
condition (Table 2). The incidence of caesarean section is not higher in this subset, suggesting the
presence of “late preterm” deliveries.
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Table 2. Baseline and main delivery data in pregnancies from egg donation according to the comorbid conditions considered.
According to the Main Conditions
p-Value
According to Groups
p-Value
No Risk Thyroid Auto-Immune Renal Other Autoimmuneand Thyroid
Renal and
Other
n (%) 178 (60.1%) 56 (18.9%) 19 (6.4%) 11 (3.7%) 32 (10.8%) 75 (25.3%) 43 (14.5%)
Age (years), median
(min–max) 44 (31–56) 43 (33–50) 44 (34–51) 43 (34–47) 45 (33–52) 0.5956 43 (33–51) 43 (33–52) 0.7599
Parity, n. first (%) 151 (84.8%) 48 (85.7%) 19 (100%) 11 (100%) 30 (93.8%) 0.1497 67 (89.3%) 41 (95.3%) 0.2608
BMI (kg·m−2), median
(min–max)
22.7
(16.8–33.7)
21.5
(17.6–33.3)
21.8
(19.4–34.4)
24.6
(18.7–34.0)
25.2
(15.6–35.5) 0.2246
21.6
(17.6–34.4)
24.9
(15.6–35.5) 0.0267
Hypertension during
pregnancy, n (%) * 31 (17.4%) 18 (32.1%) 5 (26.3%) 7 (63.6%) 13 (40.6%) 0.0005 23 (30.7%) 20 (40.6%) 0.0865
Gestational
hypertension, n (%) 31 (17.4%) 18 (32.1%) 4 (21.1%) 5 (45.5%) 2 (6.2%) 0.0073 22 (29.3%) 7 (16.3%) 0.1145
Pre-eclampsia, n (%) 16 (9.0%) 6 (10.7%) 1 (5.3%) 4 (36.4%) 6 (18.8%) 0.0336 7 (9.3%) 10 (23.3%) 0.0390
Centiles at birth,
median (min–max) 60 (1–100) 48 (1–99) 54 (4–100) 59 (1–95) 44 (0–90) 0.0949 48 (1–100) 46 (0–95) 0.4862
Caesarean section, n
(%) 128 (71.9%) 39 (69.9%) 17 (89.5%) 8 (72.7%) 18 (56.2%) 0.0177 56 (74.7%) 26 (60.5%) 0.0072
Size for GA
Small, n (%)
Adeq, n (%)
Large, n (%)
12 (6.7%)
138 (77.5%)
28 (15.8%)
4 (7.1%)
47 (83.9%)
5 (8.9%)
3 (15.8%)
13 (68.4%)
3 (15.8%)
3 (27.3%)
7 (63.6%)
1 (9.0%)
5 (15.6%)
27 (84.4%)
0 (0%)
0.0595 ** 7 (9.3%)60 (80.0%)
8 (10.7%)
8 (18.6%)
34 (79.1%)
1 (2.3%)
0.1139
Pre-term
<37, n (%)
<34, n (%)
<32, n (%)
24 (13.5%)
10 (12.8%)
7 (3.9%)
9 (16.1%)
3 (5.4%)
2 (3.5%)
2 (10.5%)
0
0
3 (27.3%)
1 (9.0%)
0
10 (31.3%)
4 (12.5%)
2 (6.3%)
0.1014
0.4293
0.7800
11 (14.7%)
3 (4.0%)
2 (2.7%)
13 (30.2%)
5 (11.6%)
2 (4.7%)
0.0441
0.1142
0.5681
eGFR EPI: glomerular filtration rate calculated with the EPI formula; BMI: body mass index; GA: gestational age; PE: preeclampsia; Adeq. Adequate. HT Hypertension * Hypertension in
pregnancy: all cases regardless of previous hypertension. Gestational hypertension is hypertension during pregnancy in previously normotensive patients. ** Chi Square test for the
difference in the distribution. Significant results in bold.
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The prevalence of small for gestational age babies was apparently not affected by the presence
of comorbidity (considered all together), but was twice as frequent after egg donation than in the
control population (Table 1). More in detail, in the subset of women who underwent egg donation,
the presence of renal, immunologic or other comorbidity was associated with a higher prevalence of
small for gestational age babies, with respect to no risk cases or to individuals with a history of thyroid
diseases (Table 2).
3.3. Characteristics of the Patients with at least One Measure of Serum Creatinine
To further analyse the relationship between kidney function and maternal-foetal outcomes, we
analysed the kidney function data available during pregnancy. Due the particular characteristics of the
study population (delivery in a public hospital, but assisted fertilisation procedure often performed
in a private structure, frequently outside Italy), creatinine assessment, which is not a part of routine
assessments in pregnancy, was available in only 42% of the cases, generally only at delivery.
In this context, creatinine was more frequently assessed in complicated pregnancies, mainly in the
context of preeclampsia and preterm delivery (Table 3). This is also witnessed by the association of
creatinine availability with preeclampsia (24.2% vs. 1.7%) and with small for gestational babies (12.9%
vs. 6.4%).
Table 3. Comparison of subsets of egg donation pregnancies with or without an available creatinine test.
All sCr Available sCr notAvailable p-Values
n (%) 296 (100%) 124 (41.9%) 172 (58.1%)
Age (years), median (min–max) 44 (31–56) 44 (31–56) 43 (33–52) 0.0813
Parity, n. first (%) 259 (87.5%) 116 (93.6%) 143 (83.1%) 0.0077
BMI (kg·m−2), median
(min–max)
22.7 (15.6–35.5) 22.6 (15.6–35.5) 22.6 (16.8–33.7) 0.4934
Presence of comorbidity
Autoimmune, n (%)
Thyroid, n (%)
Renal, n (%)
Other, n (%)
None, n (%)
19 (6.4%)
56 (18.9%)
11 (3.7%)
32 (10.8%)
178 (60.1%)
11 (8.9%)
21 (16.9%)
10 (8.1%)
21 (16.9%)
61 (49.2%)
8 (4.7%)
35 (20.3%)
1 (0.6%)
11 (6.4%)
117 (68.0%)
0.0001 **
Centile at birth, median
(min–max) 55 (0–100) 54 (0–100) 58 (1–100) 0.0908
Pre-eclampsia, n (%) 33 (11.1%) 30 (24.2%) 3 (1.7%) <0.0001
Hypertension during
pregnancy, n (%) * 74 (25.0%) 64 (51.6%) 10 (5.8%) <0.0001
Gestational hypertension, n (%) 60 (20.3%) 51 (41.1%) 9 (5.2%) <0.0001
Caesarean section, n (%) 210 (70.9%) 98 (79.0%) 112 (65.1%) 0.0094
Size for GA
Small, n (%)
Adeq, n (%)
Large, n (%)
27 (9.1%)
232 (78.4%)
37 (12.5%)
16 (12.9%)
97 (78.2%)
11 (8.9%)
11 (6.4%)
135 (78.5%)
26 (15.1%)
0.0610 **
Pre-term
<37, n (%)
<34, n (%)
<32, n (%)
48 (16.2%)
18 (6.1%)
11 (3.7%)
33 (26.6%)
11 (8.9%)
6 (4.8%)
15 (8.7%)
7 (4.1%)
5 (2.9%)
<0.0001
0.0887
0.3868
eGFR EPI: glomerular filtration rate calculated with the EPI formula; BMI: body mass index; GA: gestational age;
PE: preeclampsia; Adeq. Adequate; sCr: Serum creatinine. HT Hypertension. * Hypertension in pregnancy: all cases
regardless of previous hypertension. Gestational hypertension is hypertension during pregnancy in previously
normotensive patients. ** Chi Square test for the difference in the distribution. Significant results in bold.
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3.4. Relationship between Serum Creatinine and eGFR and Materno-Foetal Outcomes
In the context of a “negative selection” of patients with egg-donor pregnancies, the patients
with higher creatinine or lower glomerular filtration rates were not different from those with lower
creatinine (or higher e-GFR) in terms of age, presence of all comorbidities, parity and BMI.
A higher creatinine level was significantly associated with preeclampsia, gestational hypertension
and pre-term delivery; conversely, the incidence of small for gestational age babies was not different
across eGFR groups (Table 4).
Table 4. Comparison of egg donation pregnancies according to serum creatinine and eGFR.
According to Creatinine (mg/dL)
p-Values
According to eGFR (mL/min)
p-Values
sCr ≥ 0.67 sCr < 0.67 GFR < 90 GFR ≥ 90
n (%) 68 (54.8%) 56 (45.2%) 38 (30.6%) 86 (69.4%)
Age, median (min–max) 44 (32–55) 44 (31–56) 0.8363 45 (38–55) 44 (31–56) 0.1993
Parity, n. first (%) 64 (94.1%) 52 (92.9%) 0.7770 36 (94.7%) 80 (93.0%) 0.7214
BMI (kg·m−2), median
(min–max)
22.0 (15.6–35.5) 22.8(17.1–34.4) 0.8889 22.3 (15.6–34.0) 22.8 (17.1–35.5) 0.8816
No comorbidity, n (%) 31 (45.6%) 30 (53.6%) 0.3781 18 (47.4%) 60 (69.8%) 0.7878
Centiles at birth, median
(min–max) 54 (0–98) 55 (1–100) 0.4483 40 (0–98) 58 (0–100) 0.1172
Pre-eclampsia, n (%) 24 (35.3%) 6 (10.7%) 0.0015 15 (39.5%) 15 (17.4%) 0.0085
Hypertension during
pregnancy, n (%) * 43 (63.2%) 21 (37.5%) 0.0045 29 (76.3%) 35 (40.7%) 0.0003
Gestational
hypertension, n (%) 31 (45.6%) 20 (35.7%) 0.2681 19 (50.0%) 32 (37.2%) 0.1838
Creatinine (mg·dL−1),
median (min max)
0.75 (0.67–1.94) 0.57(0.26–0.66) <0.0001 0.86 (0.69–1.94) 0.63 (0.26–0.86) <0.0001
GFR-EPI (mL·min−1),
median (min-max)
87 (31–114) 114 (93–151) <0.0001 78 (31–89) 108 (90–151) <0.0001
Caesarean section, n (%) 53 (77.9%) 45 (80.4%) 0.7432 32 (84.2%) 66 (76.7%) 0.3484
Size for GA
Small, n (%)
Adeq, n (%)
Large, n (%)
9 (13.2%)
55 (80.9%)
4 (5.9%)
7 (12.5%)
42 (75.0%)
7 (12.5%)
0.4350 6 (15.8%)29 (76.3%)
3 (7.9%)
10 (11.6%)
68 (79.1%)
8 (9.3%)
0.8033 **
Pre-term
<37, n (%)
<34, n (%)
<32, n (%)
25 (36.8%)
9 (13.2%)
5 (7.4%)
8 (14.3%)
2 (3.6%)
1 (1.8%)
0.0050
0.0607
0.1522
16 (42.1%)
6 (15.8%)
4 (10.5%)
17 (19.8%)
5 (5.8%)
2 (2.3%)
0.0098
0.0728
0.0507
eGFR EPI: glomerular filtration rate calculated with the EPI formula; BMI: body mass index; GA: gestational age; PE:
preeclampsia; Adeq. Adequate. HT Hypertension. * Hypertension in pregnancy: all cases regardless of previous
hypertension. Gestational hypertension is hypertension during pregnancy in previously normotensive patients.
** Chi Square test for the difference in the distribution. Significant results in bold.
ROC curves support the significant relationship between serum creatinine and e-GFR, analysed as
continuous variables, preterm delivery and preeclampsia. The area under the curve is approximately
70% in both cases (Figure 1).
The Youden index for the relationship between e-GFR and preterm delivery or pre-eclampsia
is at ≤96 mL/min, and is at >0.64 mg/dL for preterm, and >0.63 mg/dL for the relationship between
pre-eclampsia and serum creatinine. Interestingly, both indexes were in proximity of median values,
respectively 0.67 mg/dL for serum creatinine and 103 mL/min for e-GFR (Table 2).
3.5. Multivariate Analysis
The multivariate analysis, shown in Tables 5 and 6, suggests that the presence of pre-pregnancy
comorbidity (renal diseases and other relevant disorders) is associated with a roughly double risk for
preeclampsia and preterm delivery (both statistically significant: Preeclampsia: OR: 2.53; delivery
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<37 weeks: 2.56), while, even if only comorbidity is retained in the last step, statistical significance is
not reached in the case of small for gestational age babies (OR 2.43).
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The multivariate analysis, shown in Tables 5 and 6, suggests that the presence of pre-pregnancy 
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preeclampsia and preterm delivery (both statistically significant: Preeclampsia: OR: 2.53; delivery <37 
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In the cohort in which serum creatinine assessment was available, the importance of this covariate
is higher than that of comorbidity, and statistical significance is once more reached for preeclampsia
and preterm delivery (OR 17.27 for preeclampsia) (Table 6).
In both cohorts (all cases and only patients with one assessment of serum creatinine), none of the
covariates was significantly associated with early preterm delivery, defined as <34 or <32 gestational weeks.
3.6. Analysis of Timing of Delivery
Figure 2 shows the Kaplan Maier analysis (outcome: timing of delivery) sorting patients according
to the presence of baseline comorbidity. The presence of baseline comorbidity is significant and remains
so in the subset of patients with serum creatinine assessment.
J. Clin. Med. 2019, 8, 1806 10 of 15
Table 5. Multivariate analysis of different outcomes: all cases.
Preeclampsia p-Values OR
CI 95% OR
Lower Higher
First step
Age (dichotomised at the median: 44y) 0.326 1.456 0.688 3.082
BMI (dichotomised at 30 kg/m2) 0.306 1.781 0.589 5.381
Parity (1st vs. other) 0.165 0.236 0.031 1.807
Comorbidity (renal and other) 0.056 2.355 0.979 5.667
Last step Parity 0.152 0.227 0.030 1.725
Comorbidity (renal and other) 0.035 2.513 1.066 5.923
Delivery < 37 Weeks p-Values OR
CI 95% OR
Lower Higher
First step
Age (dichotomised at the median) 0.910 0.963 0.504 1.840
BMI (dichotomised at 30 kg/m2) 0.694 1.244 0.418 3.700
Parity (1st vs other) 0.914 0.946 0.342 2.615
Comorbidity (renal and other) 0.023 2.477 1.136 5.398
Last step Comorbidity (renal and other) 0.015 2.565 1.198 5.488
Small for Gestational Age p-Values OR
CI 95% OR
Lower Higher
First step
Age (dichotomised at the median) 0.757 0.876 0.380 2.020
BMI (dichotomised at 30 kg/m2) 0.291 0.325 0.040 2.617
Parity (1st vs other) 0.484 0.586 0.131 2.622
Comorbidity (renal and other) 0.048 2.634 1.011 6.866
Last step Comorbidity (renal and other) 0.060 2.453 0.961 6.257
Legend: OR: odds ratio; CI: confidence intervals. BMI: body mass index. First and last step shown in tables
(complete analysis available in Table S1). Significant results in bold.
Table 6. Multivariate analysis of different outcomes: cases with creatinine assessment.
Preeclampsia p-Values OR
CI 95% OR
Lower Higher
First step
Age (dichotomised at the median) 0.472 1.342 0.603 2.986
BMI (dichotomised at 30 kg/m2) 0.339 1.478 0.664 3.291
Parity (1st vs. other) 0.312 0.340 0.042 2.756
Comorbidity (renal and other) 0.880 1.063 0.480 2.357
sCreat. (dichotomised at the median) <0.001 15.809 4.631 53.968
Last step sCreat. (dichotomised at the median) <0.001 17.277 5.125 58.238
Delivery <37 weeks p-Values OR
CI 95% OR
Lower Higher
First step
Age (dichotomised at the median) 0.864 1.075 0.467 2.474
BMI (dichotomised at 30 kg/m2) 0.616 0.689 0.161 2.955
Parity (1st vs. other) 0.972 1.031 0.186 5.711
Comorbidity (renal and other) 0.346 1.596 0.603 4.224
sCreat. (dichotomised at the median) 0.062 2.315 0.958 5.593
Last step sCreat. (dichotomised at the median) 0.029 2.545 1.100 5.892
Small for Gestational Age p-Values OR
CI 95% OR
Lower Higher
First step
Age (dichotomised at the median) 0.550 1.402 0.463 4.243
BMI (dichotomised at 30 kg/m2) 0.585 0.543 0.061 4.865
Parity (1st vs. other) 0.779 1.377 0.148 12.830
Comorbidity (renal and other) 0.082 3.038 0.867 10.644
sCreat. (dichotomised at the median) 0.535 0.687 0.210 2.251
Last step Comorbidity (renal and other) 0.141 2.333 0.755 7.210
Legend: OR: odds ratio; CI: confidence intervals. BMI: body mass index. Note: Age median: 44 years; sCreat.
Serum creatinine: median: 0.67 mg/dL; First and last step shown in tables (complete analysis available in Table S2).
Significant results in bold.
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The presence of a higher serum creatinine or a lower eGFR is likewise significantly correlated
with timing of delivery (Figure 3).
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4. Discussion
Egg donation is increasingly being used as a fertilization procedure. It has proved to be effective in
“extreme” cases of infertility or early ovarian failure, but involves a higher risk for adverse pregnancy
outcomes, including pre-term delivery, preeclampsia and related disorders and giving birth to a child
that is small for gestational age [7–17].
While several studies have addressed obstetric and procedure-related risk factors, as well as at
maternal age, the role of immunological diversity and the role of baseline maternal comorbidity have
not yet been fully addressed.
Various maternal conditions are considered as potentially affecting maternal-foetal outcomes
in spontaneous pregnancies; however, less is known about their effect on pregnancies obtained by
assisted fertilization techniques. Seeking to determine whether the “high risk” procedure of egg
donation offsets the effect of baseline comorbidity, we undertook the present retrospective analysis,
testing the effect of different classes of comorbidity on the outcomes of pregnancies after egg donation.
Furthermore, within the limits later discussed in detail, we tried to explore the relationship of kidney
function in this context, taking also into account the relationship between preeclampsia and long-term
kidney health [28–32].
As expected in a relatively old cohort of pregnant women, comorbidity was relatively common.
3.7% of the women were affected by a chronic kidney disease, which was however recognized as a high
risk condition in only one case (a kidney transplant recipient); 6.4% had a history of an autoimmune
disorder other than lupus and not a cause of kidney disease (all of them in remission); thyroid diseases,
once more in metabolic balance, were frequently reported (18.9%), probably also because of the
attention paid to these conditions in women with reduced fertility, while other relevant comorbidities,
including baseline hypertension and diabetes or previous neoplasia, were reported in 10.8% of the
pregnancies (Tables 1 and 2).
The different comorbidities do not appear to play the same role: a history of thyroid disorders
and of immunologic diseases was not associated with an increase in adverse pregnancy outcomes.
Conversely, kidney diseases and other relevant comorbidities were associated with approximately
twice as many preterm deliveries and cases of preeclampsia, while the increase in small for gestational
age babies did not reach statistical significance in univariate and multivariate analysis (Tables 2 and 5).
The presence of pre-conception comorbidity significantly affects the kinetics of delivery, as was
shown using the Kaplan Meier curves (Figure 2).
Given the importance of the kidney function in determining pregnancy outcomes, we further tried
to analyze the subset of patients with available kidney functional data [20–24,26]. This subset accounts
for only about 40% of all cases; selection was not random, since serum creatinine was more commonly
available in women with baseline comorbidity, preeclampsia or preterm delivery, while age, parity and
BMI were equally distributed (Table 3). This finding stresses the importance of higher awareness of the
role of kidney function and of systematic assessment of serum creatinine in all pregnancies (and even
more so in pregnancies with potential risk factors, including egg donation). Such a policy may also
allow preemptive interventions, such as aspirin prophylaxis, and strict monitoring in patients with
reduced kidney function.
Within the limits of a negative selection of cases, preeclampsia and pre-term delivery were significantly
associated with higher creatinine levels, and consequently lower e-GFR levels. Interestingly, the association
is present with a cut-point that is still in the normal serum creatinine range, defined using Youden’s index
(Figure 1, Tables 4 and 6).
The close association between pregnancy outcomes and kidney function has to be viewed with
caution. First of all the selection is probably biased, and a higher number of cases with suboptimal
kidney function may be present in the subset of cases with available data; the low number of data did
not allow correlating severity of preeclampsia or early delivery with creatinine level. However, the
relationship between complications and higher creatinine level suggests, in keeping with the data in the
literature, that adding more non-complicated pregnancies would strengthen the results. Furthermore,
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available kidney functional data were mainly measured shortly before delivery, and, in this context, it
is not possible to conclude that there is a cause effect relationship between relative kidney function
reduction and complications. However, the association is close enough to suggest that kidney function
should be monitored from preconception counseling throughout pregnancy in all women undergoing
egg donation.
This study has the strong point of novelty, being the first one addressed at establishing the role of
preconception comorbidity, in a population of women with pregnancies obtained via heterologous egg
donation. However, it suffers from relevant methodological limitations: the assessment of comorbidity
was retrospective and based upon clinical charts, and it is possible that the attention to classic risk
factors for infertility (such as thyroid or immunologic diseases) was higher in comparison with other
conditions. This is also suggested by the fact that only one of the patients with a clinical history of
chronic kidney disease had been identified and referred to the multidisciplinary follow-up facility.
In this regard, the experience discussed in this study supports the need for an in-depth analysis of
comorbidity in women undergoing egg donation, and hypothesizes that timely referral to specialized
care could reduce the more than two-fold increase in preeclampsia and preterm delivery we observed.
From a research standpoint, our data make it possible to define a prospective data set that should be
gathered for future analyses.
Within these limits, and in the wait for a prospective study, we feel that our analysis is worth
being shared, as it draws attention to two crucial elements, baseline comorbidity and kidney function,
whose influence is not offset by the effect of the complex fertilization procedure, and which should be
acknowledged and systematically controlled as potential targets for reducing the incidence of adverse
maternal-fetal outcomes in pregnancies from heterologous egg donation.
5. Conclusions
Risks associated with pregnancy after egg donation is significantly influenced by baseline comorbidity.
Furthermore, within the limit of incomplete data and of a negative selection of the cases with available data,
pregnancy outcomes are associated with higher creatinine levels, even within the normal serum-creatinine
range. While further studies are needed to determine the cause and effect relationship of this association,
the association is close enough to suggest that kidney function should be monitored from preconception
counseling, throughout pregnancy in all women, and in particular, in high risk situations, including
women undergoing egg donation.
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